‘

INTERNATIONAL CANCER INSTITUTE

ICI_NORVATIS CAPACITY BUILDING EDUCATION PROGRAM FOR SICKLE CELL DISEASE

CSE200: ICI Sickle Cell Disease Education Program

2nd September 2020 to 16th December 2020

PROGRAM DIRECTOR/PRINCIPLE INVESTIGATOR

Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist and Hematologist

Executive Director, International Cancer Institute

P.O. BOX 8088-30100, Eldoret-Kenya

Office: +254 718 473 446 Mobile: +254 700 522 149

Email: chiteasirwa@gmail.com or chite@intercancer.com

Web: www.intercancer.com

Goal and Objective:

The goal of the ICI_Norvatis Capacity Building Education Program for Sickle Cell Disease is to create awareness amongst healthcare professionals across all cadres in a Multidisciplinary team approach geared towards enhancing the standards of care for Sickle Cell Disease (SCD) in East Africa.

Target Audience

The primary target audience for this course comprises the multidisciplinary clinical Sickle Cell care team members including, but not limited to, physicians; fellows; residents; researchers; SCD nurse practitioners and SCD nurses; SCD pharmacists, SCD PharmTechs; SCD clinical officers; physician assistants; Laboratory scientists and technicians, and other allied health care professionals.

Learning Objectives

At the end of this educational activity (over the 16 weeks duration), participants should be able to:

1. Describe the epidemiology, molecular basis, presentation, and natural history of SCD and the variant sickle cell syndromes.
2. Describe the techniques for screening and the diagnosis of SCD; correctly interpret electrophoresis and HPLC traces.
3. Understand the pathophysiology and clinical manifestations of sickle cell disease; acute pain crises and progressive organ damage.
4. Describe the management of specific major acute complications, including acute chest syndrome, painful crisis, stroke, etc.
5. Describe the long-term complications od SCD (including orthopaedic, ophthalmic, renal, pulmonary, endocrine, and fertility issues) and their management, in particular the need for comprehensive multidisciplinary care.
6. Understand the use of disease-modifying agents in the management of SCD
7. Understand gene therapy, stem cell transplant, and novel therapies in SCD treatment.
8. Explain the appropriate use of transfusion in SCD.
9. Describe the complications, assessment, and treatment of transfusional iron overload
10. Demonstrate a working knowledge and practical competency for acute and chronic pain management in patients with sickle cell disease.
11. Design a health maintenance program for Pediatrics, Adolescents, and Young Adults with SCD
12. Understand the comprehensive Sickle Cell Disease Management guidelines.

Lecture Schedule (16 weeks)